NASDAQ
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)....
Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and BioAtla (NASDAQ: BCAB - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based...
Mirum Pharmaceuticals, Inc. (MIRM) M&A Call Transcript...
Mirum Pharmaceuticals said on Monday it will acquire Bluejay Therapeutics in a deal worth up to $820 million, adding a late-stage experimental drug for a severe liver disease to its portfolio....
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics,...
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?...
Mirum Pharmaceuticals has been a big winner in 2025 thanks to the success of its flagship product, Livmarli. Livmarli should continue to gain momentum in 2026....
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript...
Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome....
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that the first participant has been enrolled in the BLOOM Phase 2 clin...
No price data available for this timeframe.